

Medicare Advantage Medical Benefit Drug Policy



An independent licensee of the Blue Cross and Blue Shield Association

Medical benefit drug policies are a source for Blue Cross and Blue Shield of Nebraska Medicare Advantage medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and therefore subject to change.

Effective Date: 04/14/2022

Opdivo® (nivolumab)

HCPCS: J9299

Policy:

Requests must be supported by submission of chart notes and patient specific documentation.

- A. Coverage of the requested drug is provided when all the following are met:
 - a. Treatment must follow the Food and Drug Administration (FDA) approved indications or National Comprehensive Cancer Network (NCCN) guidelines when it is a Category 1 or 2A recommendation
 - i. Must be used with concomitant treatment according to FDA indication or NCCN Category 1 or 2A recommendation
 - b. Must be prescribed by, or in consultation with, an oncologist or hematologist
 - c. No prior failure of a programmed death receptor-1 (PD-1 or PD-L1) inhibitor
 - d. Patient is not receiving therapy for a chronic condition, such as an autoimmune disease, that requires treatment with a systemic immunosuppressant
 - e. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2

- B. Quantity Limitations, Authorization Period and Renewal Criteria
 - a. Quantity Limit: Align with FDA recommended dosing
 - b. Authorization Period: Aligns with FDA recommended or guideline supported treatment duration and provided for up to 6 months at a time
 - c. Renewal Criteria: No evidence of disease progression or unacceptable toxicity

***Note: Coverage may differ for Medicare Part B members based on any applicable criteria outlined in Local Coverage Determinations (LCD) or National Coverage Determinations (NCD) as determined by Center for Medicare and Medicaid Services (CMS). See the CMS website at <http://www.cms.hhs.gov/>. Determination of coverage of Part B drugs is based on medically accepted indications which have supported citations included or approved for inclusion determined by CMS approved compendia.

Background Information

- Opdivo is a programmed death receptor-1 (PD-L1)-blocking antibody indicated for the following:
 - Patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab

- Patients with melanoma with lymph node involvement or metastatic disease who have undergone complete resection, in the adjuvant setting
- Adult patients with resectable (tumors ≥ 4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy
- Adult patients with metastatic non-small cell lung cancer expressing PD-L1 ($\geq 1\%$) as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, as first-line treatment in combination with ipilimumab
- Adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy
- Patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Opdivo
- Adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab
- Patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab
- Patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib
- Patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy
- Adult patients with classical Hodgkin lymphoma that has relapsed or progressed after:
 - Autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or
 - 3 or more lines of systemic therapy that includes autologous HSCT
- Patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy
- Adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection of urothelial carcinoma
- Patients with locally advanced or metastatic urothelial carcinoma who:
 - Have disease progression during or following platinum-containing chemotherapy
 - Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
- Adult and pediatric patients 12 years of age and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, as a single agent or in combination with ipilimumab

- Patients with hepatocellular carcinoma who have been previously treated with sorafenib in combination with ipilimumab
 - Patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease who have received neoadjuvant chemoradiotherapy
 - Patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy
 - Patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy
- The National Comprehensive Cancer Network (NCCN) guidelines category 1 and 2A recommendations are based on uniform NCCN consensus that the recommendations are appropriate. Treatment regimens have been studied and shown to be efficacious when administered as listed in the guidelines. Category 2B and 3 recommendations do not have a high level of evidence to support use and also do not have a uniform consensus from the NCCN panel that the recommendations are appropriate.
 - There are no studies to support use of Opdivo following failure. NCCN treatment guidelines also do not recommend use of Opdivo or other PD-L1 checkpoint inhibitors following a previous failure.
 - Opdivo has not been studied in patients on chronic immunosuppressant therapy and therefore, should not be used in patients on chronic immunosuppressants.
 - Opdivo has not been studied in patients with an ECOG performance status of greater than 2 and therefore, should not be used in patients with an ECOG score greater than 2.

References:

1. Opdivo [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; September 2021.
2. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. *Lancet Oncol.* 2017 Mar; 18 (3): 312-22.
3. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. *Lancet Oncol.* 2017 Sep; 18 (9): 1182 - 91.
4. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. *NEJM.* 2015 Jul 2; 373 (1): 23 - 34.
5. Ferris RL, Blumenschein Jr G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. *NEJM.* 2016 Nov 10; 375 (19): 1856 – 67.
6. Yau T, Kang Y, Kim T, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. *JAMA Oncol.* 2020; 6 (11): e204564.
7. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma (CheckMate 238). *NEJM.* 2017; 377: 1824 - 35.
8. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. *NEJM.* 2018; 378: 1277 – 90.
9. Overman MJ, Lonardi S, Wonk KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. *J Clinical Oncol.* 2018; 36 (8): 773 – 9.
10. National Comprehensive Cancer Network. Melanoma: cutaneous (Version 2.2022). 2022 Jan 26. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf. Accessed on February 25, 2022.

11. National Comprehensive Cancer Network. Non-small cell lung cancer (Version 1.2022). 2021 Dec 7. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed on February 25, 2022.
12. National Comprehensive Cancer Network. Malignant pleural mesothelioma (Version 1.2022). 2021 Dec 22. Available at: https://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf. Accessed on February 25, 2022.
13. National Comprehensive Cancer Network. Kidney cancer (Version 4.2022). 2021 Dec 21. Available at: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed on February 25, 2022.
14. National Comprehensive Cancer Network. Hodgkin lymphoma (Version 2.2022). 2022 Feb 23. Available at: https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf. Accessed on February 25, 2022.
15. National Comprehensive Cancer Network. Head and neck cancers (Version 1.2022). 2021 Dec 8. Available at: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed on February 25, 2022.
16. National Comprehensive Cancer Network. Bladder cancer (Version 1.2022). 2022 Feb 11. Available at: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed on February 25, 2022.
17. National Comprehensive Cancer Network. Hepatobiliary cancers (Version 5.2021). 2021 Sept 21. Available at: https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed on February 25, 2022.
18. National Comprehensive Cancer Network. Esophageal and esopagogastric junction cancers (Version 2.2022). 2022 Feb 11. Available at: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Accessed on February 25, 2022.
19. National Comprehensive Cancer Network. Colon cancer (Version 3.2021). 2021 Sept 10. Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed on February 25, 2022.
20. National Comprehensive Cancer Network. Gastric cancer (Version 2.2022). 2022 Jan 11. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed on February 25, 2022.

Policy History		
#	Date	Change Description
1.2	Effective Date: 04/14/2022	Updated approval length to allow for FDA recommended dosing or up to 6 months at a time
1.1	Effective Date: 04/08/2021	Updated to remove the renewal authorization period and only allow for a 6 months approval at a time.
1.0	Effective Date: 04/16/2020	Medical Policy established -

* The prescribing information for a drug is subject to change. To ensure you are reading the most current information it is advised that you reference the most updated prescribing information by visiting the drug or manufacturer website or <http://dailymed.nlm.nih.gov/dailymed/index.cfm>.